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Summary
Partial agonists produce submaximal activation of li-
gand-gated ion channels. To address the question of
partial agonist action at the NR1 subunit of the NMDA
receptor, we performed crystallographic and electro-
physiological studies with 1-aminocyclopropane-1-car-
boxylic acid (ACPC), 1-aminocyclobutane-1-carbox-
ylic acid (ACBC), and 1-aminocyclopentane-1-carboxylic
acid (cycloleucine), three compounds with incremen-
tally larger carbocyclic rings. Whereas ACPC and
ACBC partially activate the NMDA receptor by 80%
and 42%, respectively, their cocrystal structures of
the NR1 ligand binding core show the same degree of
domain closure as found in the complex with glycine,
a full agonist, illustrating that the NR1 subunit pro-
vides a new paradigm for partial agonist action that is
distinct from that of the evolutionarily related GluR2,
AMPA-sensitive receptor. Cycloleucine behaves as an
antagonist and stabilizes an open-cleft conformation.
The NR1-cycloleucine complex forms a dimer that is
similar to the GluR2 dimer, thereby suggesting a con-
served mode of subunit-subunit interaction in AMPA
and NMDA receptors.
Introduction
Present in most cells throughout the kingdom of life,
ligand-gated ion channels participate in a vast number
of signaling pathways. Ligand-gated ion channels pos-
sess separate ligand binding and ion channel domains,
and agonist interaction with the ligand binding domain
generates conformational changes that propagate to
the ion channel, opening a conductive transmembrane
pore. There is little understanding at the level of atomic
detail of the conformational states occupied by ligand-
gated ion channels upon the binding of full and partial
agonists. Furthermore, because partial agonists elicit
submaximal activation of the ion channel, they are use-
ful molecules with which to probe relationships be-
tween agonist binding, conformational changes, and
ion channel activation. As suggested from studies by
del Castillo and Katz (del Castillo and Katz, 1957), a
partial agonist in ligand-gated ion channels is a ligand
that produces an open channel probability of less than
1 upon occupancy of all binding sites. Over the in-
tervening years, and in the absence of atomic reso-*Correspondence: jeg52@columbia.edulution structures, numerous models have been put
forth to explain the phenomenon of partial agonism.
One common model is rooted in the Monod-Wyman-
Changeux model for allosteric proteins (Monod et al.,
1965). In this model, the ligand-gated ion channel occu-
pies two states—a closed or inactive T state and an
open state or active R state—full agonists are maxi-
mally effective, or efficacious, at shifting the equilibrium
to the open state, while partial agonists are less effec-
tive (Li et al., 1997). While this model is appealing in its
simplicity, in one ligand-gated ion channel, the AMPA-
sensitive GluR2 receptor, partial agonists induce a
spectrum of conformational states in the agonist bind-
ing portion of the receptor channel (Mayer and Arm-
strong, 2004). To elaborate our understanding of partial
agonist action in another class of ionotropic glutamate
receptor, the N-methyl-D-aspartate (NMDA) receptor
subfamily, we embarked on ligand binding, crystallo-
graphic, and electrophysiological studies using a series
of compounds that differ by a single methylene (-CH2-)
group.
Ionotropic glutamate receptors (iGluRs) are ligand-
gated ion channels that participate in fast excitatory
synaptic transmission, synaptic plasticity, and neuronal
development (Dingledine et al., 1999). Upon binding ag-
onist, iGluRs open a cation-selective ion channel, al-
lowing Na+, K+, and/or Ca2+ ions to flow down their
electrochemical gradients (Hille, 2001). The protein do-
main responsible for agonist binding, the S1S2 ligand
binding core, was first identified in an AMPA receptor
(Kuusinen et al., 1995). Structural and other biophysical
studies of the GluR2 ligand binding core have resulted
in two main conclusions. First, agonist binding induces
a “domain closure” of the ligand binding core around
the agonist, with the extent of domain closure corre-
lated with the extent to which the agonist activates the
ion channel, i.e., complete domain closure leads to full
activation, and incomplete domain closure results in
partial activation (Armstrong and Gouaux, 2000; Arm-
strong et al., 2003; Hogner et al., 2002; Jin et al., 2003;
Jin and Gouaux, 2003; Jin et al., 2002); the only excep-
tion to this trend is in one protomer of the L650T mutant
of the GluR2 ligand binding core in complex with
AMPA. For this mutant, we see partially closed and fully
closed conformations of the ligand binding core, even
though AMPA behaves like a partial agonist (Armstrong
et al., 2003). Second, the ligand binding cores are ar-
ranged as dimers in a “back-to-back” fashion, with the
dimer interface playing an important role in receptor
desensitization (Horning and Mayer, 2004; Sun et al.,
2002).
NMDA receptors are related to AMPA receptors in
amino acid sequence and biological function but are
obligatory heteromeric receptors composed of NR1
and NR2 and/or NR3 subunits (Chatterton et al., 2002;
Danysz and Parsons, 1998; Dingledine et al., 1999).
Moreover, AMPA and NMDA receptors have different
requirements for activation, i.e., the binding of both gly-
cine and glutamate are required for NMDA receptor ac-
tivation (Johnson and Ascher, 1987), NMDA receptors
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receptors there is a negative allosteric coupling be-
tween the glycine (NR1) and glutamate (NR2) sites (for
a recent review, see Erreger et al., 2004). Therefore, we
set out to determine whether the GluR2 paradigm of
partial agonist action applies to NMDA receptors, first
focusing on the NR1, glycine binding subunit. Pre-
viously, we showed that the NR1 ligand binding core
has a structure similar to that of GluR2 (Furukawa and
Gouaux, 2003). However, on the basis of the first series
of structures, we found that the partial agonist D-cyclo-
serine yielded a domain closure that was similar to that
of glycine, a result that we would not have predicted
from the AMPA receptor paradigm. Because this single
observation suggested that NMDA and AMPA recep-
tors might conform to different models of partial ago-
nist action, we investigated the structural and func-
tional behavior of the NMDA receptor in the presence
of a series of partial agonists.
Three cyclic homologs of glycine—1-aminocyclopro-
pane-1-carboxylic acid (ACPC), 1-aminocyclobutane-
1-carboxylic acid (ACBC), and 1-aminocyclopentane-1-
carboxylic acid (cycloleucine)—bind to the NR1, glycine
site of the NMDA receptor (Hood et al., 1989; Nadler et
al., 1988; Nahum-Levy et al., 1999; Watson et al., 1989;
Watson and Lanthorn, 1990). These compounds have
carbocyclic rings of three, four, and five atoms, respec- F
tively (Figure 1). ACPC, ACBC, and cycloleucine, how-
(
ever, have dramatically different affinities for the NR1 (
ligand binding core, and while the first two are partial t
tagonists, cycloleucine is an antagonist. To probe the
amechanism of partial agonism in NMDA receptors, we
asolved the structures of the NR1 ligand binding core
din complexes with ACPC, ACBC, and cycloleucine. In
c
addition, we measured the binding of the ligands to the t
soluble NR1 ligand binding core and carried out elec-
trophysiological recordings on wild-type and NR1 mu-
tants to measure the extent of ion channel activation f
and to test the significance of specific receptor-ligand A
interactions. u
m
Results
N
TNR1 S1S2 Displacement Experiments
NR1 S1S2 is the water-soluble, ligand binding core of l
tthe glycine binding NR1 subunit and is composed of
polypeptide segments S1 and S2 (Furukawa and Gou- u
caux, 2003). ACPC, ACBC, and cycloleucine are amino
acid derivatives with three-, four-, and five-membered s
tcarbocyclic rings (Figure 1A). To determine the relative
affinities of these compounds at the glycine site of the c
aNR1 receptor, we carried out radioligand displacement
experiments using the competitive antagonist [3H]- m
7MDL105,519 (Baron et al., 1996), the results of which
are illustrated in Figure 1B. On the basis of the dis- 2
tplacement experiments, the Ki values for ACPC, ACBC,
and cycloleucine are 4.80 ± 0.62 M, 0.831 ± 0.055 mM, m
aand 15.3 ± 2.49 mM, respectively. As a comparison, the
Ki value of glycine is 26.4 M (Furukawa and Gouaux, v
t2003), indicating that ACPC binds with a 5.5-fold higher
affinity than glycine, and ACBC and cycloleucine bind t
much more weakly than glycine, with 31-fold and 580-
fold lower affinities, respectively. The K value, there- uiigure 1. Ligand Displacement Experiments
A) Chemical structures of ACPC, ACBC, and cycloleucine.
B) Purified S1S2 was incubated with 20 nM of the competitive an-
agonist, [3H]-MDL105,519, in the presence of various concentra-
ions of ACPC (open circles), ACBC (squares), and cycloleucine (tri-
ngles). The data points were then fit to a single binding site model
s described in Experimental Procedures. The IC50 values for the
isplacement of [3H]-MDL105,519 by ACPC, ACBC, and cycloleu-
ine were 21.2 ± 2.4 µM, 3.67 ± 0.23 mM, 67.4 ± 9.4 mM, respec-
ively. Error bars show ± SEM.ore, reflects the subtle differences between ACPC,
CBC, and cycloleucine. Indeed, the molecular vol-
mes increase by onlyw11 Å3 with the addition of each
ethylene group.
MDA Receptor Activation
o determine the efficacy of ACPC, ACBC, and cyclo-
eucine on NMDA receptor activation, we carried out
he two-electrode voltage-clamp (TEVC) experiments
sing NR1/NR2B subunits expressed in Xenopus oo-
ytes. Shown in Figure 2 are records and graphical
ummaries of the TEVC experiments. Here we assume
hat glycine is a full agonist and produces maximal re-
eptor activation. ACPC and ACBC dose-dependently
ctivate the NR1/NR2B NMDA receptor and yield maxi-
al current amplitudes, relative to glycine, of 80.1% ±
.0% and 41.6% ± 0.5%, respectively (Figures 2A and
B). The potencies of ACPC and ACBC for receptor ac-
ivation parallel their behavior in the binding experi-
ents with ACPC and ACBC having EC50 values that
re 2.1-fold lower and 42-fold higher than the EC50
alue for glycine, respectively. Cycloleucine, by con-
rast, is a competitive antagonist and does not activate
he NMDA receptor at concentrations up to 50 mM.
Because ACPC is a weak antagonist at the NR2 sub-
nit glutamate binding site (Nahum-Levy et al., 1999),
Partial Agonism at Glycine Site of NMDA Receptor
73Figure 2. Ion Channel Activity of ACPC, ACBC, and Cycloleucine
on NR1/NR2B NMDA Receptors
(A) Maximal currents evoked by saturating concentrations of the
three ligands using two-electrode voltage-clamp, where the re-
cordings were taken from a single oocyte. Glycine (100 M), ACPC
(10 M), and ACBC (1 mM) were each applied for 10 s, as indicated
by the black bar above each record. Glutamate, at a concentration
of 0.1 mM, was in all solutions. The maximal current responses
(Imax) elicited by ACPC and ACBC were 80.1 ± 7.0 and 41.6 ±
0.5%, respectively.
(B) Shown are the results of dose-response experiments in the pres-
ence of glycine (open squares), ACPC (open circles), ACBC (open
triangles), and cycloleucine (closed circles). The EC50 values and Hill
coefficients (nHill) for glycine, ACPC, and ACBC were 0.583 ± 0.030
M (nHill = 1.89 ± 0.14), 0.275 ± 0.030 M (nHill = 1.96 ± 0.45), and
24.3 ± 1.8 M (nHill = 1.02 ± 0.07), respectively. Each dose-response
was measured on at least three different oocytes.
(C) The effect of glutamate concentration on NMDA receptor acti-
vation by either ACPC or ACBC. The NR1/NR2B receptors were
activated by ACPC (1 or 10 M) in combination with glutamate (100
M or 1 mM), and the current responses were normalized to the
response elicited by 100 M of each glutamate and glycine applied
to the same oocyte. Each data point is an average of separate
experiments from four different oocytes. Inhibition of glycine-
dependent activation by cycloleucine was also examined. Glycine
(0.1, 3, and 100 M) was applied in the presence or absence of
cycloleucine (50 mM) (n = 5). Error bars show ± SEM.we wanted to show that the apparent partial agonist
behavior of ACPC was not simply due to its antagonist-
like action at the NR2B glutamate site. Therefore, we
carried out experiments using an ACPC concentration
at the “top” of the ACPC dose-response curve and
either 0.1 mM or 1.0 mM glutamate. We found that
increasing the glutamate concentration from 0.1 mM to
1.0 mM did not substantially alter the maximal current
evoked by saturating concentrations of ACBC (Figure
2C), thereby indicating that the partial agonist activity
of ACPC was not simply due to competitive antagonist
action at the NR2B site. In agreement with the previous
studies, our experiments showed that ACPC and ACBC
are partial agonists and cycloleucine is a competitive
antagonist at NR1/NR2B NMDA receptors (Watson and
Lanthorn, 1990).
Crystallographic Analysis of NR1 S1S2 Complexes
To understand the molecular basis for the activity of
ACPC, ACBC, and cycloleucine at NMDA receptors, we
cocrystallized the NR1 S1S2 ligand binding core with
each of the three compounds. As summarized in Table
1, all of the crystals diffracted beyond 1.8 Å resolution,
and the NR1 S1S2/ACPC complex diffracted particu-
larly well, to 1.4 Å resolution. The crystal structures
were solved by molecular replacement (MR), using the
intact glycine bound structure as a search model for
the ACPC and ACBC complexes. For the cycloleucine
complex, the MR probes were domains 1 and 2 of the
NR1 S1S2/glycine structure. The resulting MR solutions
were then subjected to crystallographic refinement, as
summarized in Table 2. In the ACPC and ACBC bound
structures, there are no electron density features for the
four N-terminal and one C-terminal residues. The trace
of the ACPC complex is continuous and includes loop
1 (residues 439–449), a region that was disordered in all
previous NR1 S1S2 structures and that is also disor-
dered in the ACBC and cycloleucine complexes. The
continuous density for the NR1 S1S2/ACPC complex is
probably due, at least in part, to the completeness of
the diffraction data, even in the highest-resolution shell
at 1.45–1.40 Å resolution. In the cycloleucine bound
structure, 4 residues at the N terminus and 7 residues
at the C terminus are disordered, as are residues 439–
449 in loop two, for both protomers in the asymmetric
unit. The conserved disulfide bond between Cys744
and Cys798 is visible in the electron density maps for
the ACPC and ACBC complexes, but in the cycloleu-
cine complex, the last 6 residues of S2 are disordered
in both protomers, and this region includes Cys798 of
the conserved disulfide bond.
All structures solved in this study share a “clam-
shell”-like configuration with two domains identical
to those reported previously (Furukawa and Gouaux,
2003) and similar to those of GluR2 (Armstrong et al.,
1998). In all of the complexes, unambiguous electron
density defines the position and orientation of each li-
gand, allowing us to map specific ligand-receptor con-
tacts (Figure 3A). ACPC is bound to the receptor by
a hydrogen bond network composed of 3 residues in
domain 1 and 2 residues in domain 2 (Figure 3B). The
α-carboxy group of ACPC forms a salt bridge with
Arg523 on domain 1 and participates in hydrogen
Neuron
74Table 1. Data Collection Statistics
Ligand ACPC ACBC Cycloleucine
Space group P212121 P212121 P1
Unit cell (Å) a = 41.4, b = 72.6, c = 96.3 a = 41.5, b = 72.7, c = 96.6 a = 53.2, b = 53.2, c = 67.5
α = 110.1, β = 91.6, γ = 108.7
No. per a.u.a 1 1 2
Lambda (Å) 0.9795 0.9795 0.9796
dmin (Å)b 1.4 (1.45–1.40) 1.5 (1.55–1.50) 1.8 (1.86–1.80)
Total obs. 306,308 233,997 222,936
Unique obs. 55,999 43,342 57,310
Rmerge (%)c,d 8.7 (33) 8.9 (34) 5.9 (25)
Completenessd 96.6 (100.0) 93.4 (95.6) 95.2 (96.3)
I/σ (I)d 20.0 (3.6) 21.3 (3.4) 25.7 (3.69)
Redundancyd 5.3 (4.1) 5.2 (4.2) 3.8 (3.69)
a Number of protein molecules per asymmetric unit (a.u.).
b Rmerge = ΣhΣi(|Ii(h)| − |<I(h)>|)/ΣhΣiIi(h), where Ii(h) is the observed intensity, and <I(h)> is the mean intensity observed from multiple
measurements.
c Values in parentheses define the resolution range at the highest shell of data.
d Values in parentheses are for the last shell data.main chain positions. For the cycloleucine complex, ACPC, ACBC, and cycloleucine complexes, respec-
Table 2. Refinement Statistics
Ligand ACPC ACBC Cycloleucine
Resolution (Å) 15–1.4 15–1.5 15–1.8
Rwork (%)a 19.9 20.1 18.7
Rfree (%)b 22.0 23.7 22.4
No. of protein atoms 2251 2174 4203
No. of waters 428 357 685
No. of ligand atoms 7 8 18
Average B value
Overall 21.6 24.7 26.3
Main 18.1 21.4 23.1
Side chain/water 24.2 27.3 28.8
Ligand 11.9 20.7 17.3
Rms deviation
Bonds (Å) 0.005 0.006 0.005
Angles (°) 1.30 1.24 1.18
B values
Bonds 1.4 1.2 1.8
Angles 2.0 1.9 2.5
Ramachandran plotc 91.8/8.2/0/0 92.0/8.0/0/0 91.3/8.7/0/0
a Rwork = Σ||Fo| − |Fc||/Σ|Fo|, where Fo and Fc denote observed and calculated structure factors, respectively.
b 10% of the reflections were set aside for the calculation of the Rfree value.
c Percentage of amino acids which distribute in most favored/allowed/generous/disallowed regions of Ramachandran plot.bonds with the main chain nitrogen and the side chain t
shydroxyl of Ser688, similar to the NR1 S1S2/glycine
complex. At the α-amino group of ACPC, there is a salt
lbridge to Asp732, as well as hydrogen bonding interac-
tions with the backbone carbonyl of Pro516 and the r
Vhydroxyl of Thr518. In terms of direct ligand-receptor
interactions, the ligand-receptor contacts made by c
3ACBC and cycloleucine are similar to those made by
ACPC (Figures 3C–3E). Nevertheless, there are impor- b
stant differences between the complexes, and some of
these differences include variations in the conformation t
Tof Ser688 and Val689 and the position of a key water
molecule (W1) in the binding pocket. When comparing i
dthe glycine bound structure to the ACPC and ACBC
complexes, the volume of the cavity occupied by the A
lligand increases from w56 Å3 to 72 Å3 and 116 Å3, re-
spectively; the expansion of the cavity involves side l
gchain reorientations and small shifts of side chain andhere is no “cavity” because cycloleucine is partially
olvent exposed.
The NR1 ligand binding pocket, while replete with po-
ar and charged residues, also contains hydrophobic
esidues, such as Phe484 on domain 1 and Trp731/
al689 on domain 2, that create a nonpolar surface and
onstrain ligand-receptor interactions (Figures 3E and
F). Localized at the end of strand 12 and positioned
eneath the ligands, Trp731 “senses” the volume of the
ubstituent attached to the α-carbon of the ligand. As
he volume of the substituent increases, the indole of
rp731 moves “down” and away from the ligand bind-
ng pocket, resulting in a change in the side chain χ1
ihedral angle of 4.8°, 6.0°, and 10.0° in the ACPC,
CBC, and cycloleucine complexes, respectively. To il-
ustrate that the indole of Trp “rides” along with the
igand, we note that the closest contacts between li-
ands and the indole ring are 3.4, 3.5, and 3.5 Å in the
Partial Agonism at Glycine Site of NMDA Receptor
75Figure 3. Binding of ACPC, ACBC, and Cycloleucine to NR1 S1S2
(A) Fo-Fc “omit” maps of the three ligands contoured at 4.0 σ.
(B) Illustration of ACPC in the NR1 S1S2 binding pocket, showing ACPC in ball-and-stick (black) and transparent CPK representation, where
oxygen is red, nitrogen is blue, and carbon is black. Selected residues surrounding ACPC are also shown in ball-and-stick representation,
and the hydrophobic amino acids are shown in transparent CPK view. The hydrogen bonds between ACPC, key side chains, and water
molecules are indicated by dashed lines.
(C) Interactions between ACBC and binding site residues, using the same representations as shown in panel (B).
(D) Interactions between cycloleucine and key binding site residues, also using the same representation as in panel (B). In the cycloleucine
complex, the expanded cleft permits the entry of two additional water molecules (W3 and W4). In addition, the opened cleft is illustrated by
the increase in separation between the side chains of F484 and W731.
(E) Relative positions of key residues in the ligand binding pocket of NR1 S1S2 where residues participating in ligand binding have been
flattened onto the plane of the page. Subsites A (red) are occupied by hydrogen bond acceptors, while subsite B (blue) is occupied by a
hydrogen bond donor. One water molecule (W1) forms a direct hydrogen bond to ligand in the ACBC and cycloleucine structures. Hydrophobic
amino acids (yellow circles) are also shown and are “under” the agonist subsite.
(F) Superposition of domain 1 of the glycine (yellow), ACPC (green), ACBC (blue), and cycloleucine (red) complexes, illustrating the relative
positions of R523, F484, V689, W731, and helix F. While the ligands, R523, and F484 superimpose relatively well, the positions of V689, W731,
and helix F differ substantially, because the carbocyclic ring “pushes” on the side chains of residues V689 and W731.tively. Therefore, the ligand volume is directly felt by the
side chain of Trp731 and can lead to an opening of the
binding site cleft if the ligand is sufficiently large, as
described below.
The isopropyl group of Val689 makes contacts with
full and partial agonists, and the distances between the
CG2 methyl group of Val689 and either the α-carbon
atom of glycine or the closest carbon atoms in the ring
of ACPC and ACBC are 5.37, 4.96, and 4.45 Å, respec-
tively. In the ACPC and ACBC complexes, there are
changes in the side chain and main chain torsion an-
gles proximal to Val689 (Figure 3F). For example, at
Val689 the χ dihedral angles in the glycine, ACPC, and1ACBC bound states are 185.9°, 177.5°, and 179.8°, re-
spectively. At the polypeptide main chain, the ψ torsion
angles of Ser688 and the f torsion angles of Val689
are −30.9°, −21.2°, and −15.7° and −70.0°, −63.1°, and
−65.1°, for the glycine, ACPC, and ACBC complexes,
respectively. While these dihedral angle changes are
modest, they nevertheless result in a rotation of helix F
in the ACPC and ACBC complexes, relative to the gly-
cine complex, by w11° around an axis parallel to helix
F. This rotation relocates Tyr692 on helix F and alters
contacts between Tyr692 and Phe754, where the latter
residue is located at the “clamshell” interdomain hinge.
Phe484 is a key residue that “caps” the ligand bind-
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76ing sites in NR1 S1S2. In AMPA receptors, the equiva- p
dlent residue is tyrosine, and the aromatic ring occupies
a similar position as the aromatic ring of Phe484 in NR1. p
aIn NR1 S1S2, as in GluR2 S1S2, the nonpolar portion
of agonists, proximal to the α-carbon, participate in hy-
drophobic interactions with the aromatic ring, and the P
distances between the α-carbon of ACPC, ACBC, and A
cycloleucine and the plane of the phenyl group are 3.3, c
3.5, and 3.5 Å, respectively (Figure 3F). For NR1 S1S2, p
however, the edge of Phe484 interacts with the indole p
of Trp731, forming a hydrophobic interdomain contact. 8
Thus, as the ring of the ligand expands, in going from a
ACPC to cycloleucine, and the binding pocket ex- p
pands, the hydrophobic interdomain interactions be- F
tween Phe484 and Trp731 are altered. s
r
tComparison of Domain Closure
and Receptor Activation u
WTo evaluate the relative disposition of domain 1 and do-
main 2 in the three complexes, we superposed domain s
A1 of each of the complexes on domain 1 of the NR1
S1S2/glycine complex. The glycine, ACPC, and ACBC
acomplexes superimpose well (Figure 4A), but the cyclo-
leucine complex does not: it adopts an “open”-cleft (
bconformation, most similar to the NR1 S1S2 com-
plex with 5,7-dichlorokynureic acid (DCKA) (Furukawa r
hand Gouaux, 2003). However, when domains 1 and 2
are separated and individually superimposed on each a
cother, using the glycine, ACPC, ACBC, and cycloleucine
complexes, we find that the root mean squared (rms) t
fdeviations for α-carbon positions are less than 0.33 Å
for domain 1 and 0.69 Å for domain 2, therefore indicat- t
Aing that the domains behave as relatively rigid bodies,
with domain 2 being slightly more variable in conforma- t
ttion. Because there are two protomers in the asymmet-
ric unit of the cycloleucine complex, we compared the i
lcrystallographically independent structures and found
that they superimposed with a rms deviation on α-car- t
bon position of 0.1 Å.
To define the separation of domains 1 and 2, i.e., the m
5extent of “domain closure,” we superimposed domain
1 of two structures and then determined the trans- f
Aformation required to superimpose domain 2. Using the
glycine bound structure as a reference, we determined f
Bthe extent of domain closure for all of the available NR1
S1S2 structures. By plotting the extent of domain clo- a
gsure versus maximal current, we determined the corre-
lation between domain closure and ion channel activa- g
ttion (Figure 4C). For the full and partial agonists of NR1,
i.e., glycine, D-serine, ACPC, ACBC, and D-cycloserine, F
fwe find that they vary in the extent of domain closure
by 0.5° or less. By contrast, the cycloleucine com- a
tplexes adopt a conformation in which domains 1 and 2
are more open by 18°. Because we solved many struc- e
ttures of the GluR2 S1S2 ligand binding core and have
carried out complementary electrophysiological experi- d
cments, we also plot the structure and current data for
GluR2 in Figure 4C. As evident from inspection of the 1
sgraph, the relationships between domain closure and
ion channel activation are different for NR1 and GluR2. t
iFor GluR2, partial agonists induce less domain closure
than full agonists, i.e., domains 1 and 2 do not come
pas close together, and full agonists induce the sameextent of domain closure. By contrast, for NR1, full andartial agonists induce essentially the same degree of
omain closure. Thus, the molecular mechanisms of
artial agonist action at NMDA and AMPA receptors
re distinct.
artial Agonist-Induced Conformational Changes
detailed comparison of the glycine, ACPC, and ACBC
omplexes reveals that even though the three com-
lexes have the same degree of domain closure, the
artial agonist complexes differ in the conformation of
residues, from Thr749 to Ser756 on strand 14, located
t the hinge region of the “clamshell” which spans the
arts of domains 1 and 2 (Figure 5A). As illustrated in
igures 5B and 5C, Fo-Fc “omit” electron density maps
how a clear and continuous electron density for this
egion of the glycine and ACBC bound crystal struc-
ures. Although not shown, the ACPC complex also has
nambiguous density for this portion of the protein.
hy does this stretch of the second interdomain β
trand adopt a different conformation in the ACPC and
CBC complexes?
The second β strand (strand 14) participates in an
ntiparallel β sheet-like structure with the first strand
strand 10), although there are only two hydrogen
onds between residues 537–539 of the first strand and
esidues 750–755 of the second strand. One of these
ydrogen bonds, between the carbonyl group of Leu538
nd amino group of Phe753, is conserved in the gly-
ine, ACPC, and ACBC structures, but the second con-
act, involving the amino group of Leu538, switches
rom the carbonyl group of Phe754 in the glycine struc-
ure to the carbonyl group of Phe753 in the ACPC and
CBC structures. Therefore, a few interstrand interac-
ions, together with the apparent stability of an al-
ernate conformation and local conformational changes
n the agonist binding pocket, as discussed below, al-
ow residues 749–756 to adopt two different conforma-
ions.
At the “top” of the hinge region, Phe754 makes aro-
atic-aromatic contacts with Tyr692 in helix F (Figure
D). In the glycine complex, these residues interact via
ace-to-edge contacts (yellow), while in the ACPC and
CBC complexes the interaction is best described as
ace-to-face contacts (green and blue, respectively).
ecause Phe754 is close to the agonist binding pocket
nd appears to play a role in the conformational hetero-
eneity of the second interdomain β strand, we investi-
ated the functional consequences of changing Phe754
o a leucine (F754L) and an alanine (F754A). For the
754L and F754A mutants, their respective EC50 values
or glycine are 19- and 7.4-fold greater, and for ACBC
re 9.0- and 8.2-fold greater than the wild-type recep-
or, as illustrated in Figures 5E and 5F and Table 3 (Hirai
t al., 1996). While the F754A mutation did not affect
he extent of ACBC activation, the F754L mutation re-
uced the efficacy of ACBC to 13.8%, relative to gly-
ine. In addition, both mutations resulted in at least a
0-fold decrease in ACBC potency. Together, these re-
ults support the suggestion that F754 and its interac-
ions with helix F play an important role in agonist bind-
ng and gating.
Val689, at the base of helix F, is another residue that
lays an important role in agonist-receptor interactionsas described above and that is near Phe754 and
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(A) Superposition of the ACPC (green), ACBC (blue), and cycloleucine (red/magenta) complexes using the α-carbon atoms of domain 1. The
amino acids in the ligand binding pocket, as well as the ligands themselves, are shown in stick representation. The α-carbon atom of the
glycine residue in the Gly-Thr linker between S1 and S2 is shown as a sphere and is colored the same as the α-carbon trace.
(B) Pairwise superpositions of the NR1 S1S2/glycine complex (yellow) and the ACPC (green), ACBC (blue), and cycloleucine (red) complexes,
again using α-carbon atoms from only domain 1 for the superposition and showing the ligands and the α-carbon atom of the glycine in the
Gly-Thr linker.
(C) Relationship between domain closure and maximal response induced by ligands. Domain closure is defined as the rotation that is required
to superimpose domain 2 of a particular complex following the superposition of domain 1 onto the domain 1 of the NR1 S1S2/glycine
complex. For GluR2, the AMPA bound structure was used as a reference, fully closed structure. Agonist efficacies of cycloleucine and DCKA
were set to zero, the efficacy of D-cycloserine at the NMDA receptor was taken from Sheinin et al. (2001), and the efficacies of the GluR2
agonists were from Mayer and Armstrong (2004). The crystal structures used in this analysis were, for NR1 S1S2, 1PB7 (Glycine), 1PB8 (D-
serine), 1PB9 (D-cycloserine), and 1PBQ (DCKA); and for GluR2 1M5B (Tet-AMPA), 1FTM (AMPA), 1MM7 (QUIS), 1FTJ (GLU), 1M5C (BrHIO),
1MQJ (HW), 1MQI (FW), 1MQH (BW), 1MQG (IW), 1P1N (L650T-KA), 1FTK (kainate), 1FTL (DNQX), 1FTO (APO), and 1FOT (ATPO) for GluR2.
The linear fit to the points yields a correlation coefficient of 0.59 for NR1 and 0.92 for GluR2.Tyr692. To examine the role of Val689 in partial agonist
recognition, we mutated the valine to an alanine
(V689A) and found, remarkably, that in the context of
the V689A mutant, ACBC was nearly as efficient as gly-
cine in promoting receptor activation. Therefore, we
suggest that by truncation of the side chain at position
689, the larger ACBC agonist is now able to stabilize
the closed-cleft conformation of the ligand binding do-
main almost as well as glycine. However, the V689A
mutation increases the EC50 values for glycine (2.1-fold)
and ACBC (16-fold), indicating that the mutation also
affects relative apparent affinities (Figures 5E and 5F).
Interdomain Interactions in NR1 and GluR2
Ligand Binding Cores
To better understand the interactions that are responsi-
ble for stabilizing the NR1 S1S2 and GluR2 S1S2 ligand
binding cores in closed-cleft conformations, we ana-lyzed the noncovalent contacts between domain 1 and
domain 2. As illustrated in Figure 6, there are multiple
sites of contact between domains 1 and 2 in both struc-
tures. However, in the NR1 structure there are more
contacts between domain 1 and domain 2, and the two
major contact sites are located on either side of the
agonist binding pocket. In particular, for NR1 S1S2,
Asn499, Gly485, and Lys483 on domain 1 form contacts
with Gln686 and Glu712 on domain 2 via hydrogen
bonds that are conserved among the full and partial
agonist bound structures. Importantly, these polar resi-
dues are well defined by their respective electron den-
sities, indicating that they tend to occupy a single con-
formational state (Figure 6B).
The Cycloleucine-Bound NR1 S1S2 Forms a Dimer
The cycloleucine bound NR1 S1S2 ligand binding core
forms a back-to-back dimer that is similar to the GluR2
Neuron
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(A) Superposition of the α-carbon traces of the glycine (yellow), ACPC (green), and ACBC (blue) structures illustrates the variability in confor-
mation of the second interdomain β strand (strand 14), which is highlighted with an ellipse.
(B) Electron density for the interdomain strand in the ACBC complex, spanning residues 748–757.
(C) Fo-Fc “omit” density for the same region in the glycine complex. In both panels (B) and (C), the maps were contoured at 2.5 σ.
(D) Illustration of the side chain conformational differences of residues Y692 and F754, the two key residues located at the base of helix F
and within strand 14. Side chains in the glycine, ACPC, and ACBC structures are yellow, green, and blue, respectively.
(E) Glycine dose-response curves for the wild-type and the site-directed mutants of the NR1 subunit, measured from NR1/NR2B receptors
expressed in Xenopus oocytes, in the presence of 1 mM L-glutamate.
(F) ACBC dose-response curves for the same set of NR1/2B receptors as in (E) in the presence of 1 mM L-glutamate. Shown in Table 3 is a
summary of the EC50 and Imax properties of the receptors. Error bars show ± SEM.S1S2 dimer (Figure 7) (Armstrong and Gouaux, 2000). a
dIndeed, superposition of domain 1 of the NR1 S1S2/
cycloleucine structure on domain 1 of the kainate I
Lbound GluR2 S1S2 yields a rms deviation of 0.97 Å for
all equivalent α-carbon atoms in the dimers, showing g
tthat the dimers are remarkably similar. As with the
GluR2 S1S2 dimer, the subunit-subunit contacts are t
tmediated primarily by helix D on one protomer with he-
lix J on the 2-fold related protomer (Armstrong and 2
4Gouaux, 2000; Sun et al., 2002).
Analysis of the dimer interface reveals that each pro- d
atomer buries w1050 Å2 of solvent-accessible surface ux, 2000; Stern-Bach et al., 1998; Sun et al., 2002). In
Table 3. Parameters of Ligand-Dependent Activation Curves in Wild-Type and Mutant Receptors
Glycine ACBC Glutamate
NR1 Construct EC50 (M) nHill n EC50 (M) Imax (%)a nHill n EC50 (M) nHill n
NR1-wt 0.583 ± 0.030 1.89 ± 0.14 6 23.4 ± 1.5 41.6 ± 0.3 1.06 ± 0.07 4 3.74 ± 0.16 1.58 ± 0.10 3
NR1-V689A 1.23 ± 0.09 1.53 ± 0.15 4 364 ± 14 93.4 ± 0.4 1.45 ± 0.07 5 4.36 ± 0.33 1.63 ± 0.17 3
NR1-F754L 11.0 ± 0.2 1.54 ± 0.04 4 210 ± 12 13.8 ± 0.1 1.11 ± 0.06 7 3.97 ± 0.32 1.39 ± 0.13 3
NR1-F754A 4.29 ± 0.19 1.34 ± 0.07 4 193 ± 9 40.7 ± 0.6 1.18 ± 0.06 8 5.89 ± 0.74 1.38 ± 0.21 5
a Each current amplitude was calculated with a control evoked by a saturated concentration of glycine (1 mM).rea upon dimer formation and associates through van
er Waals contacts and six hydrogen bonds. Residues
le519, Ala524, and Gln525 on and around helix D,
eu774 and Leu777 on helix J, and the methylene
roups of Lys531 on the first interdomain β strand par-
icipate in contacts between the protomers. Also similar
o the GluR2 dimer, solvent molecules play an impor-
ant role in the NR1 homodimer, and there are at least
2 water molecules with temperature factors below
0 Å2 that are located in the dimer interface. A key resi-
ue in the GluR2 dimer is Leu483 (Armstrong and Gou-
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and GluR2 S1S2 Ligand Binding Cores
(A) Illustration of the noncovalent contacts
between domains 1 and 2, demonstrating
that the NR1 subunit has contact sites that
lie on both sides of the ligand binding
pocket. Shown is a solvent-accessible sur-
face representation of domain 2, viewed
from domain 1. Domain 1 has been omitted
from the view and from the calculation of the
solvent-accessible surface of domain 2.
Atoms participating in hydrogen bond be-
tween domains 1 and 2 and between domain
2 and ligands are colored purple and green,
respectively. Residues involved in hydropho-
bic interactions are orange. To help define
the orientation of domain 2, the residues co-
valently connected to domain 1 are marked
with squares.
(B) Key residues involved in interdomain hy-
drogen bonds are well ordered in the partial
agonist bound complexes of NR1 S1S2.
Shown in blue mesh is a Sigmaa-weighted
2Fo-Fc map contoured at 1.6 σ. Three hy-
drogen bonds are presented with dashed
lines, and domains 1 and 2 are colored green
and yellow, respectively.NR1, the equivalent residue is asparagine, and in the
NR1 S1S2 homodimer the primary amide group of the
asparagine side chain makes a hydrogen bond with the
backbone carbonyl of Leu774 on the 2-fold related pro-
tomer.
In electron density maps, we found nonprotein elec-
tron density in the dimer interface that is suggestive of
one or more bound molecules and/or ions (Figure 7).
The dumbbell-shaped density is at the “top” of the di-
mer interface, is nestled between four lysine side
chains, two from each subunit, and is about 3 Å × 6 Å
at a 4 σ contour level in an Fo-Fc map. Even though
we carried out many crystal soaking experiments and
subsequent X-ray crystallographic analyses, using a
large number of small molecules and ions, we have
been unable to conclusively determine the molecular
nature of the density. Crystals soaked in molecules
such as pyrophosphate and malonic acid, at concen-
trations up to 10 mM, have dumbbell-shaped density
that appears stronger and more well-defined than crys-
tals produced in the “standard” crystallization solution.
It is also possible that the density is due to L-lactate
contamination from the polyethylene glycol employed
in the crystallization (Zhang and Tanner, 2004), although
the density is too large for one L-lactate molecule and
too small for two. Thus, whereas the origin of the den-
sity is uncertain, a tentative conclusion is that the den-sity is a small anionic molecule, perhaps bearing two
negative charges at each end of the molecule.
Discussion
The problem at hand concerns the conformational
states that partial agonists induce in the NR1 subunit
of the NMDA receptor and how these conformational
states modulate the activity of the receptor. Two dif-
ferent models for the conformational states induced by
full and partial agonists are illustrated in Figure 8 (Arm-
strong et al., 2003). Here, binding of agonist simply
shifts the equilibrium between the closed state and the
open state of the channel to the right. Full agonists pro-
mote the greatest shift, i.e., f >> 1, while partial agonists
are less effective in stabilization of the open state, i.e.,
f > 1. An important simplifying element of the model in
Figure 8 is that both partial and full agonists stabilize
the same open conformational state of either NMDA or
AMPA receptor. In the case of AMPA-sensitive GluR2
receptor, studies on partial agonist action at the recep-
tor have shown that the agonist binding domain of the
GluR2 receptor can adopt many conformational states,
depending on the specific stereochemical properties of
the agonist, and that the extent of conformational
change in the agonist binding domain is correlated to
the extent of receptor activation.
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Figure 7. The NR1 S1S2 Complex with Cycloleucine Forms a Dimer
in the Crystal
a(A) Superposition of the NR1 S1S2 dimer (red) and the GluR2 S1S2J
kainate dimer (green; 1FTK). This view is from the “side,” and the l
2-fold axis is vertical and in the plane of the page, and the linkers i
connecting S1 and S2 are at the “bottom” of the dimer. The nonpro- a
tein Fo-Fc density between the two subunits, contoured at 4 σ, is (shown in blue mesh, and the nearby lysine residues are drawn in
sball-and-stick representation.
t(B) View of the superimposed complexes along the molecular
2-fold axes, using the same representations as in panel (A). 2
(C) Close-up of the dimer interface, the nonprotein electron density n
in the dimer interface, and the 4 proximal lysine residues. a
p
oTo address the conformational changes in the ligand
binding core of the NMDA receptor glycine binding t
psubunit NR1 upon partial agonist binding, we used
three closely related glycine analogs that are incremen- t
stally larger by steps of w11 Å3. Because the agonists
define a graded series with increasing volume, they a
rserve as subtle probes of the conformational behavior
of the NR1 ligand binding core. Our crystallographic m
hstudies, however, show that the NR1 ligand binding
core behaves differently from the AMPA-sensitive, t
sGluR2 receptor in the presence of partial agonists. For
the NR1 subunit, partial agonists and full agonists in- i
aduce the same degree of domain closure.
While this conclusion is striking, it must be tempered oith at least two qualifications. First, we have only
tudied five full or partial agonists of the NMDA recep-
or by crystallography and electrophysiology; in the
ase of the GluR2 AMPA receptor, we have examined
ver ten full and partial agonists. Second, the NR1
1S2 structures with full and partial agonists are de-
ived from the same crystal form, and it is possible that
attice contacts, and not inherent properties of the li-
and binding domain, stabilize a single closed-cleft
onformation in the presence of both full and partial
gonists. While this is a valid concern, there are three
easons why lattice forces are unlikely to be responsi-
le for the conformational behavior of NR1 S1S2: (1)
he lattice does not restrict the conformational re-
rrangement of the second interdomain β strand, and
hus we know that the molecule is not entirely “frozen”
n the crystal lattice; (2) cocrystallization experiments
id not reveal new conditions or crystal forms for the
artial agonists, thus suggesting that the partial agonist
omplexes adopt a similar conformation, in solution, as
he full agonist complexes; (3) the GluR2 S1S2 con-
truct readily undergoes domain movements to a mod-
st extent (w3.5°) in the crystal lattice upon exchange
f full and partial agonists in the crystal (Jin and Gou-
ux, 2003), thus showing that a given crystal lattice can
upport multiple conformational states of S1S2 struc-
ures.
artial Agonist-Induced Conformational Changes
f the partial agonists ACPC and ACBC do not stabilize
he closed-clamshell state of the ligand binding core as
ffectively as glycine, yet we have nevertheless cap-
ured a closed-clamshell conformation, how are these
ncrementally larger molecules accommodated within
he ligand binding site, particularly since all of the com-
ounds are substantially larger than glycine? Like gly-
ine, the three compounds share a similar hydrogen
ond network between the carboxy and amino groups,
nd the protein and these ionic contacts differ relatively
ittle between all of the full and partial agonists stud-
ed to date. The nonpolar portions of ACPC, ACBC,
nd cycloleucine interact primarily with three residues
Phe484, Val689, and Trp731) that form a hydrophobic
urface of the binding pocket. Primarily because two of
hese residues are on domain 2, and because domain
appears to be the more “deformable” domain, the
onpolar interactions between the partial agonists/
ntagonist and receptor differ from compound to com-
ound. For example, Trp731 may “sense” the volume
f the ligand and, when the ligand is larger than ACBC,
he contacts between the ligand and the indole ring
revent complete domain closure. Val689 is also sensi-
ive to the size of the ligand, and upon increasing ligand
ize, Val689 undergoes local conformational changes
nd also appears to couple the volume of the ligand to
otations of helix F, which in turn are coupled to confor-
ational changes in the interdomain β strand, at the
inge of the clamshell. In support of the role that con-
acts between Val689 and ligand played in domain clo-
ure and receptor activation, when the valine side chain
s truncated to an alanine, ACBC is a full agonist. The
bility to compensate for larger ligand size by reduction
f the volume of specific amino acid side chains, and
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of Ligand-Gated Ion Channels Induced by
Full and Partial Agonists
(A) The ligand binding core is depicted as a
blue “clamshell,” and the ion channel portion
of the receptor is indicated by black bars.
Full and partial agonists are smaller and
larger black wedges, respectively. In this
multistate model, the ligand binding core
can occupy many conformations, depending
on the stereochemical details of the ligand.
Full agonists promote complete closure of
the ligand binding core, while partial ago-
nists promote varying degrees of incomplete
closure. The conformational changes in the
ligand binding core are somehow trans-
mitted to the ion channel domain such that
complete closure of the ligand binding core
leads to maximal open probability (full ago-
nist) and incomplete closure leads to sub-
maximal open probability (Jin et al., 2003).
(B) In this model of a ligand-gated ion channel, there are only two conformational states of the ligand binding core and the ion channel
domain. Here, full and partial agonists induce the same conformational change in the ligand binding core. Full agonists are maximally effective
at shifting the equilibrium to the right, i.e., populating the agonist bound, open-channel state, while partial agonists are less effective at
shifting the equilibrium from the closed- to open-channel state. In this model, K is the equilibrium association constant of ligand with the
receptor, Lo is the equilibrium ratio of inactive (closed ion channel) to active (open ion channel) states, and f is the factor by which ligand
binding affects the extent of receptor activation, i.e., ion channel opening. For full agonists, f >> 1, and for partial agonists, f > 1 (Li et al., 1997).thereby increase the efficacy of a partial agonist, is now
a familiar theme in glutamate receptor studies (Arm-
strong et al., 2003; Madden et al., 2004).
Multiple Conformations of the Second
Interdomain  Strand
Extensive crystallization trials of NR1 S1S2 with either
ACPC or ACBC yielded crystals that grew under condi-
tions similar to those for the glycine, D-serine, and
D-cycloserine complexes (Furukawa and Gouaux, 2003).
Therefore, even if the extent of domain closure is the
same among all full and partial agonist bound struc-
tures, the structure is possibly selected from a variety
of conformational states present in solution. Neverthe-
less in the ACPC and ACBC bound structures, the local
conformation of the second interdomain β strand (Fig-
ure 5A) adopts a conformation similar to that found in
the antagonist bound structure. This observation sug-
gests that even though ACPC and ACBC are able to
stabilize the ligand binding core in the closed-cleft con-
formation, they are not able to induce all of the confor-
mational changes that full agonists induce. Because
ACPC and ACBC do not produce a full agonist-like con-
formational change in the second interdomain β strand,
and we know from studies on GluR2 S1S2 and NR1
S1S2 that the clamshell hinge passes through the sec-
ond interdomain β strand, we suggest that the ACPC
and ACBC closed-clamshell states are less stable than
the full agonist closed-clamshell states. Therefore, in
terms of the diagram in Figure 8, ACPC and ACBC sim-
ply do not stabilize the open state of the receptor as
effectively as full agonists because they are not able to
induce all of the full agonist-like conformational re-
arrangements.
The residue Phe754 on the second interdomain β
strand is a key residue in stabilizing the conformation
of the hinge region. Phe754 maintains contact with
Tyr694 on helix F, in agonist and antagonist boundstates, and may serve to “communicate” conforma-
tional changes in the ligand binding pocket to confor-
mational changes in the clamshell hinge that in turn
lead to domain closure. In support of the indirect role
played by Phe754 in agonist binding and subsequent
conformational changes, mutations introduced at Phe754
shift the dose-response curves not only of glycine, but
also of ACPC and ACBC, to right (Figure 5).
In spite of the antagonist-like conformation of the
second interdomain β strand, why do ACPC and ACBC
stabilize a full agonist-like, closed-clamshell conforma-
tion of the ligand binding core? One possible explana-
tion is that the closed-clamshell state of the NR1 ligand
binding core is stabilized by numerous noncovalent in-
teractions, including nonpolar and polar contacts, that
are located on either side of the agonist binding pocket,
as shown in Figure 6. In GluR2, by contrast, the number
and extent of interdomain interactions are smaller. In-
deed, a recent study in which interdomain contacts in
the NR1 subunit were probed by site-directed muta-
genesis and chemical derivatization emphasize the im-
portance of domain 1-domain 2 contacts in agonist
binding and receptor activation (Kalbaugh et al., 2004).
In addition, however, it is likely that the conformational
stability and dynamical behavior of the polypeptide
main chain, in the regions of the interdomain β strands,
will also play an important role in determining the sta-
bility of the clamshell at various degrees of domain clo-
sure (McFeeters and Oswald, 2002).
Dimeric Configuration of Glycine Binding Core
The dimeric arrangement of the NR1 ligand binding
core is strikingly similar to that of the GluR2 S1S2 li-
gand binding core in its nondesensitized conformation.
Moreover, the dimerization of the ligand binding core in
glutamate receptors is now an established theme, as it
has been seen in the ligand binding cores of the GluR0
and GluR2 receptors (Armstrong and Gouaux, 2000;
Neuron
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lmate receptors are tetrameric in subunit stoichiometry
T(Laube et al., 1998; Nakagawa et al., 2005; Rosenmund
c
et al., 1998; Safferling et al., 2001; Tichelaar et al., o
2004), we can now suggest that both NMDA and a
HnonNMDA receptors are, at the level of the ligand bind-
ling core, arranged as dimers of dimers. While of course
Awe have not shown that the NR1 dimer that we see in
4our crystals of the cycloleucine complex is present in
t
the intact receptor, the fact that we do see such a dimer e
strongly suggests that in the intact receptors the ligand d
(binding cores are organized as either NR1-NR1 homo-
7dimers or NR1-NR2 heterodimers. We would argue that
swhile some experiments suggest the presence of NR1
2homodimers (Schorge and Colquhoun, 2003), further
n
experiments are required to unambiguously distinguish c
between homodimer and heterodimer arrangements. t
rThe electron density for loop 1 is continuous in the
eACPC bound NR1 ligand binding core, therefore allow-
fing us to determine its position accurately. By contrast,
the density is not continuous in the other NR1 S1S2 C
complexes studied to date. Interestingly, Regalado et D
al. proposed that loop 1 participates in an allosteric N
coupling between NR1 and NR2 ligand binding cores a
1(Regalado et al., 2001). To understand where loop 1 is
Apositioned in a dimer of ligand binding core subunits,
rwe superimposed the ACPC bound NR1 structure onto
b
the cycloleucine bound NR1 dimer. In this dimeric ar- V
rangement, loop 1 projects from diagonally related cor- c
ners of each subunit and is not in a position to interact D
Gwith the other subunit in the dimer. In the intact recep-
ptor, therefore, loop 1 probably participates in interac-
ttions between dimers.
c
An unknown molecule occupies an electropositive f
crevice in the NR1 dimer interface, and it is likely that C
this compound helps to stabilize the NR1 dimer (Figure u
C7). Two lysine residues (Lys531 and Lys769) of each
lprotomer define the binding pocket, and the four amino
igroups give rise to the positively charged character of
(
the binding site. Like cyclothiazide binding to the GluR2 D
S1S2 dimer (Sun et al., 2002), the unknown molecule t
in the NR1 dimer may stabilize the dimer by forming r
wcontacts between both subunits, although in the case
wof the NR1 dimer the bridging molecule interacts at a
different portion of the dimer interface, closer to the
L
“top” of the dimer, and the unknown molecule makes G
only polar contacts. Cyclothiazide, by contrast, makes 1
extensive polar and nonpolar interactions. Neverthe- (
iless, it has not escaped our attention that the site
7where the anionic molecule binds in the NR1 dimer
binterface may be a site of receptor modulation in iono-
o
tropic glutamate receptors. In both AMPA receptors f
and NMDA receptors there are, in most subunits, posi- G
tively charged residues that could interact with anionic p
wmolecules at the site in the dimer interface that we have
pidentified in this NR1 dimer complex.
d
iExperimental Procedures
NR1 S1S2 Purification and Crystallization
The rat NR1 S1S2 construct employed in this work is identical to w
rthat previously described (Furukawa and Gouaux, 2003) and in-
cludes two extracellular regions from Met394 to Lys544 (S1) and a
rfrom Arg663 to Ser800 (S2); the S1 and S2 segments are connectedy a dipeptide Gly-Thr linker, and there is a polyhistidine tag fol-
owed by a thrombin proteolysis site on the amino terminus of S1.
o eliminate the contamination of glycine in the protein solution,
ycloleucine was added to the buffer instead of glycine at the step
f ion exchange chromatography (IEC). Subsequently, the IEC elu-
te was extensively dialyzed against a buffer composed of 10 mM
EPES-NaOH (pH 7.0), 150 mM NaCl, and 1 mM EDTA and each
igand at concentrations of 0.1 mM, 10 mM, and 20 mM for ACPC,
CBC, and cycloleucine, respectively. All crystals were grown at
°C in hanging drops containing either 1:1 or 1:2 (v/v) ratio of pro-
ein solution (5 mg/ml) to reservoir solution. The crystallization res-
rvoir solution for the ACPC-NR1 S1S2 complex was 100 mM so-
ium cacodylate (pH 6.0), 100 mM lithium sulfate, and 23%–27%
v/v) PEG 400. The cocrystal with ACBC grew in 16%–20% PEG
50, 100 mM sodium cacodylate (pH 6.0), and 100–200 mM lithium
ulfate, and the cycloleucine cocrystal grew in 16%–20% PEG
000, 0.1 mM sodium cacodylate (pH 6.5), and 75–100 mM ammo-
ium sulfate. Crystals were flash-cooled in liquid nitrogen after
ryoprotection. For the ACPC and ACBC cocrystals, the concentra-
ion of the respective PEGs was simply increased to 30% and 24%,
espectively, while for the cycloleucine complex 18% glycerol was
mployed as a cryoprotectant. ACPC and ACBC were obtained
rom Tocris and cycloleucine was purchased from Sigma.
rystallography
iffraction data sets were collected at the X4A beamline at the
ational Synchrotron Light Source and were indexed, integrated,
nd scaled with the HKL suite of programs (Otwinowski and Minor,
997). Data collection statistics are summarized in Table 1. The
CPC and ACBC bound S1S2 structures were solved by molecular
eplacement (MR) using AMORE (Navaza, 1994) and the glycine
ound structure as a search probe. For the cycloleucine complex,
M calculation (Matthews, 1968) suggests that there are two mole-
ules per unit cell (VM of 2.5 Å3/Dalton). Because MR using the NR1
CKA complex failed, domains 1 (Leu398 to Tyr535 and Gly757 to
lu781) and 2 (Gln536 to Ser756) were separately used as search
robes. By using the separate domains, unambiguous solutions to
he rotation and translation functions were determined for the two
rystallographically independent molecules. Crystallographic re-
inements were carried out in CCP4 suite (CCP4 Project, 1994) and
NS (Brunger et al., 1998). O (Jones and Kjeldgaard, 1997) was
sed for model building and for displaying maps created by the
NS program. After refinement, the resulting structures were ana-
yzed by PROCHECK (Table 2) (Laskowski et al., 1993). Superposit-
ons and root mean square deviations were calculated by LSQKAB
Kabsch, 1976) and the relative domain closure was calculated by
ynDom (Hayward and Lee, 2002). GRASP was used to compute
he ligand volume and solvent-accessible surface area with a probe
adius of 1.4 Å (Nicholls et al., 1991). Calculation of cavity volume
as performed using Voidoo (Kleywegt and Jones, 1994). Figures
ere prepared using PyMOL (DeLano, 2002).
igand Displacement Experiments
lycine-free NR1 S1S2 was prepared by extensive dialysis against
0 mM HEPES-NaOH (pH 7.0), 150 mM NaCl, 1 mM EDTA, and 10%
v/v) glycerol at 4°C. Twenty nanograms of NR1 S1S2 was diluted
n the ligand binding buffer containing 100 mM HEPES-NaOH (pH
.0), 150 mM NaCl, 1 mM EDTA, and 10% (v/v) glycerol and incu-
ated with 20 nM [3H] MDL105,519 (Perkin-Elmer) in the presence
f various concentrations of ACPC, ACBC, or cycloleucine at 4°C
or 1 hr. The protein-ligand complexes were then recovered on
SWP 02500 membranes by vacuum filtration apparatus (Milli-
ore), as previously described (Chen and Gouaux, 1997). The filter
as washed three times with ice-cold ligand binding buffer (2 ml),
laced in scintillation cocktail, and counted for radioactivity. Kalei-
agraph was utilized for fitting of the data points using the follow-
ng formula:
(B) = (Bmax) / (1− 10∧([ligand] − log(IC50)),
here B is a recovered radioactivity, Bmax is a maximum binding of
adioactivity, [ligand] is a concentration of cold ligand, and IC50 is
concentration of cold ligand giving a half-maximum of binding of
adioactivity. K value was estimated with the formulai
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where Kd is a dissociation constant of radiolabeled compound, and
[R] is a concentration of radiolabeled compound in the reaction
mixture. The Kd value of [3H] MDL105,519 was previously measured
to be 5.86 nM (Furukawa and Gouaux, 2003). The binding experi-
ments were carried out three separate times, and each time every
condition was duplicated. The error bars indicate the standard er-
ror of the mean.
Electrophysiology
A female Xenopus laevis was anaesthetized by immersion in 0.2%
(w/v) tricaine (Sigma) solution for 20 min. Ooocytes were surgically
removed and defolliculated with collagenase and maintained in a
L15 oocyte medium (Specialty Media). cRNAs were transcribed
from the parent rat NR1_1a and NR2B DNA (Hollmann et al., 1993;
Kutsuwada et al., 1992; Monyer et al., 1992; Moriyoshi et al., 1991)
using the Ambion Message Machine kit according to the manufac-
turer’s instructions. The cRNAs were then injected into oocytes,
using 0.07 ng of NR1 and 0.03 ng of NR2B cRNA, in a total volume
of 50 nL. After injection, oocytes were incubated at 17°C, and re-
cordings were made 24–72 hr later, at room temperature. Site-
directed mutations were introduced by the quick change mutagen-
esis method with two primers having a mutation and verified by
DNA sequencing.
Two-electrode voltage-clamp recordings of oocyte currents were
performed with Axoclamp 2B amplifier (Axon Instruments), and
agarose-tipped electrodes had a resistance of 0.5-1.5 MΩ when
filled with 3 M KCl. The bath solution contained 96 mM NaCl, 2 mM
KCl, 0.4 mM BaCl2, 0.1 mM EDTA, and 20 mM HEPES-NaOH (pH
7.4). ACPC, ACBC, and cycloleucine were dissolved and diluted in
the bath solution. When cycloleucine was examined at a concen-
tration of 50 mM, the osmolarity of the solution was adjusted with
sucrose to 270 mOsm. Perfusion of the impaled oocytes was
achieved by a gravity-fed solution exchanger (RSC-200, Biologic
Science Instruments). The holding potential for all experiments, un-
less otherwise noted, was −60 mV. All electrophysiological data
were collected with HEKA Pulse software and processed with Igor.
Rundown was corrected by measuring the response to a saturating
concentration of glutamate in the beginning, middle, and end of the
agonist applications (Armstrong et al., 2003). Current amplitudes
elicited by ligands were compensated with the responses by 100
M glycine pulsed at either end of a series of ligand application.
The dose-response data was fitted with the following formula:
I = Imax / (1 + (EC50 / [ligand])∧nHill),
where EC50 is the concentration of agonist that yields half-maximal
activation, and nHill is the Hill coefficient. The data points are given
as the mean ± the standard error of the mean from at least three
distinct oocytes.
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